Jeffrey Bluestone
Known title: DirectorCIK: 0001771814
Associated companies
Transaction History
| GILD | ▲ Buy | Option Exercise | 1,165 | $79K | 8/20/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 26 | $4K | 8/20/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 335 | $21K | 8/20/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 335 | $49K | 8/20/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 1,165 | $167K | 8/20/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 1,816 | $122K | 8/20/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 1,816 | $263K | 8/20/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 1,658 | $112K | 8/20/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 1,658 | $242K | 8/20/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 26 | $2K | 8/20/2026 | View on chart |
| GILD | ▲ Buy | Grant | 1,146 | $0 | 4/30/2026 | View on chart |
| GILD | ▲ Buy | Option Exercise | 5,000 | $337K | 1/20/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 5,000 | $618K | 1/20/2026 | View on chart |
| GILD | ▼ Sell | Open Market | 5,000 | $625K | 11/28/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 5,000 | $325K | 11/28/2025 | View on chart |
| GILD | ▼ Sell | Open Market | 5,000 | $549K | 7/14/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 5,000 | $337K | 7/14/2025 | View on chart |
| GILD | ▲ Buy | Option Exercise | 5,879 | $360K | 11/26/2024 | View on chart |
| GILD | ▼ Sell | Open Market | 6,788 | $620K | 11/26/2024 | View on chart |
| GILD | ▲ Buy | Option Exercise | 4,121 | $253K | 11/26/2024 | View on chart |
| GILD | ▲ Buy | Grant | 2,444 | $0 | 5/5/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 2,223 | — | 5/3/2022 | View on chart |
| GILD | ▲ Buy | Option Exercise | 1,041 | — | 12/8/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers
Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.
Gilead Signs $1.9B Deal With Vir For T-Cell Engagers. Gilead Sciences has entered a $1.9 billion partnership with Vir to develop next-generation T-cell engagers, a move aimed at expanding its oncology pipeline. This strategic agreement coincides with the stock reaching record highs as investors show renewed interest in the healthcare sector. The deal provides a new catalyst for the company ahead of its scheduled third-quarter financial results release.